Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Product › Details

Imfinzi®

Products Next higher product group durvalumab (MEDI4736, anti-PD-L1 antibody)
Period Status 2017-05-01 registration start
Organisation Organisation MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
Document Source AstraZeneca plc. (5/1/17). "Press Release: AstraZeneca’s Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer".
     

   
Record changed: 2017-08-09

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for durvalumab (MEDI4736, anti-PD-L1 antibody)


To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px